Figures & data
Figure 1 Survival rates of A549/GemR and A549 cell lines.
![Figure 1 Survival rates of A549/GemR and A549 cell lines.](/cms/asset/14047355-f201-483a-9a35-1535a947c3e4/dott_a_12199113_f0001_b.jpg)
Figure 2 The relative expression of ILK in A549/GemR and A549 cells.
Abbreviations: ILK, integrin-linked kinase; GemR, gemcitabine resistant.
![Figure 2 The relative expression of ILK in A549/GemR and A549 cells.](/cms/asset/8af2c942-e656-46a3-b230-2cd956f9d2c3/dott_a_12199113_f0002_b.jpg)
Figure 3 The function of ILK in gemcitabine resistance.
Abbreviations: ILK, integrin-linked kinase; GemR, gemcitabine resistant; ILK, integrin-linked kinase.
![Figure 3 The function of ILK in gemcitabine resistance.](/cms/asset/e7688328-52f1-4b87-84a1-fd3671018ae1/dott_a_12199113_f0003_b.jpg)
Figure 4 The molecular mechanism of ILK in gemcitabine-resistant lung cancer.
Abbreviations: ILK, integrin-linked kinase; EMT, epithelial–mesenchymal transition; MRP1, multidrug resistant protein 1; FN, fibronectin; GemR, gemcitabine resistant.
![Figure 4 The molecular mechanism of ILK in gemcitabine-resistant lung cancer.](/cms/asset/0f847230-a080-4f26-a39f-66af75940fd5/dott_a_12199113_f0004_b.jpg)